|Day Low/High||1.70 / 1.82|
|52 Wk Low/High||1.42 / 8.12|
Seasoned Executive With Proven Track Record Building Leading Biotech Companies; Significant Experience Advancing Development Programs Into Commercial Products
Thirteen companies received Nasdaq delisting notices in December and still fail to meet exchange requirements.
Biotech watchdog Adam Feuerstein answers readers' questions about drug and health care companies.
Several stocks, including Discovery Labs, were poised to move on above-average volume Thursday.
Several stocks trading near $5, including Discovery Laboratories, were poised to move on above-average volume Wednesday.
On-Track for Q1 2011 Surfaxin Complete Response Filing
Biological Activity Test (BAT) Optimization and Revalidation Completed With All Pre-Specified Acceptance Criteria Met
Data Presented at 2010 American Thoracic Society International Conference
New Preclinical Data Presented at the 2010 Pediatric Academic Societies Annual Meeting
Earnings roundup: Children's Place profit dips, sales rise; Vail Resorts profit falls
Our senior biotech columnist answers readers' questions about Health Discovery, Discovery Labs and other newsworthy healthcare stocks.
Smart drug and biotech companies keep the FDA abreast of their clinical trial program throughout the long drug-development process.
Genzyme CEO Henri Termeer is Adam Feuerstein's Worst Biotech CEO of the Year for 2009.
Discovery Laboratories slumped on a spike in volume days after an agreement with the Food and Drug Administration cleared a path for its experimental lung drug.
Discovery Laboratories jumped on a massive spike in volume Wednesday after it reached an agreement with the FDA that clears a path for its experimental lung drug.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.